Liquid biopsy genotyping in lung cancer: Ready for clinical utility?

Wei Lun Huang, Yi Lin Chen, Szu Chun Yang, Chung Liang Ho, Fang Wei, David T. Wong, Wu Chou Su, Chien Chung Lin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.

Original languageEnglish
Pages (from-to)18590-18608
Number of pages19
JournalOncotarget
Volume8
Issue number11
DOIs
Publication statusPublished - 2017 Jan 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this